Welcome to our dedicated page for Profound Medical SEC filings (Ticker: PROF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Profound Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Profound Medical's regulatory disclosures and financial reporting.
Profound Medical Corp. introduced new real-time interventional MRI Treatment Delivery Consol (TDC) software for its TULSA-PRO® prostate ablation platform. The software is being deployed across the TULSA-PRO installed base and builds on prior TULSA-AI® modules aimed at improving procedural efficiency, physician experience, and reducing planning complexity.
The upgrade adds real-time iMRI control to put surgeons more directly in control of TULSA-PRO’s supervised robotic autonomy, along with physician-requested user-interface and hardware-control improvements. Profound states that some physicians currently perform up to four TULSA Procedures™ per system per day, and the new software is intended to provide a roadmap for customers to achieve up to six procedures per system per day
Profound Medical Corp. appointed Matthew Sobczyk as Interim Chief Financial Officer effective August 14, 2026, following the same-day resignation of CFO Rashed Dewan. Sobczyk has held progressively senior finance roles at the company since 2017, most recently as Corporate Controller.
As Interim CFO, Sobczyk will receive an annual base salary of CAD 300,414.58 and is eligible for a discretionary bonus targeted at 15% of base salary. Dewan entered into a Mutual Separation Agreement, receiving a cash severance of $375,000, employer-paid benefits for 15 months, extended exercisability of vested stock options for up to 12 months, and reimbursement of up to CAD 5,000 in legal fees.
Under a separate Contractor Services Agreement, Dewan will provide transition and advisory services from August 17, 2026 through November 25, 2026, for CAD 200 per hour and will continue vesting on 20,000 restricted share units, supporting continuity during the finance leadership transition.
Profound Medical Corp., a commercial-stage medical device company focused on interventional MRI (iMRI) procedures, reported the launch of Let’s Huddle, a global patient advocacy and community initiative supporting men and their families through the prostate care journey. Announced on August 13, 2026, the program is led by Global Patient Ambassador Leonard Wheeler, a former NFL player and prostate cancer survivor, and is designed to provide education, peer connection, survivor stories, and resources for patients and care partners.
The initiative aligns with Profound’s MRI-guided therapy platforms TULSA-PRO and Sonalleve by extending support beyond treatment delivery to include pre-diagnosis education, treatment decision support, and survivorship. Profound states that Let’s Huddle will grow through expanded educational programming, storytelling, awareness campaigns, and collaborations with healthcare providers and advocacy organizations worldwide.
Profound Medical Corp. reported revenue of $7,820 (USD in thousands) for the six months ended June 30, 2026, up from $4,832 a year earlier, driven by higher capital equipment sales and recurring non‑capital revenue. Gross profit rose to $5,779 from $3,471, while operating expenses declined to $24,866 from $28,443, narrowing the net loss to $16,593 from $26,419; basic and diluted loss per share improved to $0.46 from $0.88.
Research and development spending was stable at $10,916 for the six‑month period, while selling, general and administrative expenses decreased to $13,950 from $17,537 as the company reduced salaries and commissions, travel, consulting fees and insurance costs. Cash was $38,271 at June 30, 2026 compared with $59,723 at December 31, 2025, after $19,921 of net cash used in operating activities; a $4,507 balance on the CIBC revolving credit facility was classified as current. Management states that existing cash and product and service sales are expected to fund operating and capital needs for at least the next 12 months and confirms compliance with financial covenants under the CIBC Credit Agreement.
Profound Medical Corp. reported second quarter 2026 results with total revenue of approximately $2.5 million, up 12% year-over-year, including about $1.6 million of recurring non-capital revenue and $871,000 from capital equipment sales. Around $3.1 million of TULSA shipments slipped from late June into July and will be recognized in the third quarter; excluding this timing, management states revenue would have been about $5.6 million, or 153% higher year-over-year.
Gross margin expanded to 78%, above the company’s 70% long-term target, while operating expenses fell 16% to roughly $13.0 million, driving a net loss of about $9.5 million, or $0.26 per share, a 39% improvement from a year earlier. Cash was approximately $38.3 million at June 30, 2026. The installed base of TULSA-PRO systems reached 84, the qualified sales pipeline was estimated at about $70.0 million, and payer coverage grew by roughly 18.3 million lives, including two large employer health plans. Based on record order activity and visibility into second-half shipments, Profound reiterated its 2026 revenue outlook of approximately $25.0 million, representing 56% growth, and continues to target full-year gross margin of at least 70%.
Profound Medical Corp. reports new quality-of-life data from the Level 1 post‑market CAPTAIN randomized controlled trial comparing its MRI‑guided TULSA Procedure with robotic radical prostatectomy in men with organ‑confined, intermediate‑risk Gleason Score 7 prostate cancer.
At 1 month, there was no median change in penile length after whole‑gland TULSA, versus a 0.65 cm median reduction after robotic radical prostatectomy, with a 0.42 cm between‑arm difference from a mixed‑effects model (p<0.001). CAPTAIN enrolled 211 patients at 20 U.S. sites, two in Canada and one in Europe, aiming to show non‑inferior cancer control for TULSA with superior quality‑of‑life outcomes, including preservation of erectile function and urinary continence.
Profound Medical Corp. plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026, followed by a conference call at 4:30 p.m. Eastern Time to review the results and discuss business developments. The call will be broadcast live and archived in the Investors section of the company’s website.
Profound Medical is a commercial-stage medical device company focused on interventional MRI (iMRI) procedures. Its flagship TULSA-PRO platform enables MRI-guided, incision-free prostate ablation, while its Sonalleve system provides non-surgical MRI-guided therapy for certain bone, tumor, and gynecologic conditions.
Profound Medical Corp. announced that its MRI-guided, AI-powered, robotically driven and incisionless TULSA Procedure will be featured in multiple physician-led presentations at the Society of Robotic Surgery Annual Meeting in Fort Lauderdale, FL, scheduled for July 23-26, 2026.
Clinical talks will cover real-world outcomes, randomized trial primary safety data, single-center efficacy and safety, salvage treatment after prior therapies, and program adoption, with leading presenters from UT Southwestern and other centers. Profound will also be one of only eight companies spotlighted in the Society of Incisionless Surgery plenary session on imaging, AI and robotic autonomy.
Before the clinical program, management plans to participate in an SRS Investor Session on July 22, 2026, discussing innovative robotic technologies and TULSA-PRO. Profound describes itself as a commercial-stage medical device company focused on MRI-guided, incision-free therapies including TULSA-PRO and Sonalleve, which have clearances or approvals in multiple global markets.
Profound Medical Corp. reported the results of its 2026 annual and special shareholder meeting. Shareholders elected eight directors, including two new nominees, to serve until the next annual meeting. Support for individual directors ranged from about 79% to 91% of votes cast.
Shareholders approved the appointment of PricewaterhouseCoopers LLP as auditors, with 25,193,910 votes for and 99.497% support. They also approved an ordinary resolution confirming all unallocated restricted share units and deferred share units under the long-term incentive plan, with 9,046,376 votes for and 63.922% support versus 36.078% against. The circular notes 36,337,637 common shares outstanding as of April 2, 2026, and describes the company’s equity-based compensation, governance structure, and executive/director pay philosophy.